Angelini Pharma S.p.a. · Healthcare · Italy
High risk. 3 critical or high findings in DNS health, GDPR outside view and 1 other check.
Angelini Pharma S.p.a. is a prominent pharmaceutical company based in Italy, recognized as a top player in the pharmaceutical and healthcare sector both nationally and across Europe. The company focuses on improving patient quality of life through a portfolio of market-leading brands in areas such as brain health, pain management, antibiotic therapy, and consumer healthcare products. Their business model emphasizes research and development, production, and commercialization of specialty and consumer healthcare medicines. Angelini Pharma operates internationally with multiple country-specific subsidiaries and maintains a strong brand presence supported by certifications and employer awards. Technically, the website employs modern JavaScript libraries including jQuery, Slick Carousel, and Magnific Popup, alongside Piwik PRO for analytics and consent management. The site is well-structured, mobile-optimized, and demonstrates good SEO and accessibility practices. The presence of comprehensive privacy and cookie policies with active consent mechanisms reflects a mature approach to privacy compliance. From a security perspective, the site enforces HTTPS with strong SSL configuration and includes key security headers. No critical vulnerabilities or exposed sensitive data were detected. However, the absence of a dedicated security policy or incident response contact suggests room for improvement in transparency and readiness. Analytics usage is moderate with privacy compliance well addressed. Overall, Angelini Pharma's digital presence is professional, trustworthy, and aligned with industry standards. The website effectively supports the company's business objectives and market positioning while maintaining a solid security and privacy posture.
Scanned
NIS2 Art. 21(2)
This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.
GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.
3 findings rated critical or high. Fix these first.
DNS sends visitors and email to the right servers. Misconfigured records can cause outages or let someone redirect your traffic.
Domain expired 13 days ago
What to do: Renew domain registration immediately
These are the privacy signals visitors and data protection authorities look for under GDPR.
GDPR requires explicit consent for non-essential cookies
What to do: Implement a cookie consent banner that appears on first visit
TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.
Server supports weak protocols: TLSv1.1
What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions
Need hands-on remediation? Email guard@offseq.com
This scan found 18 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.
€25per month
Email alerts on material changes and an exportable JSON history of every change.
Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.
€39.90one-time
Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.
Each check with its score, findings and the evidence it collected.
The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.
Counted in this score
Not counted
Findings that cap the score at 49
Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.
Partial scans
When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.
Risk levels
Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.
Leaked records that mention angelinipharma.it, from OffSeq Breach.
2 subdomains affected
See the 10 newest leaked credentials
A one-off add-on to this report that lists the most recent identifier and password pairs OffSeq Breach holds for angelinipharma.it.
Select it in the checkout above.
Breach keeps ingesting new leaks, so these numbers can grow between scans.
Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.
Automated reading of the public site. Ratings are indicative.
Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.
Retrieved 2026-10-25
Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.
Reviews of this site
Share your experience with angelinipharma.it. Every review is verified by email and published after moderation.
Community rating
No published reviews yet. Be the first to review angelinipharma.it.